As the prices paid for priority review vouchers (PRVs) have crept up over the past year — the last two have sold for at least $200 million each — companies now have to make difficult decisions on …
Cochrane review dismissing amyloid drugs draws immediate backlash
A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins


